What is Lantern Pharma Inc Annual Net Profit?

Lantern Pharma Inc Annual Net Profit fell 5.31% in the last year to $15.96 M. Its sector's average net profit growth for the last fiscal year was -32.45%.

What is Lantern Pharma Inc Price to Earning Ratio?

Lantern Pharma Inc Price to Earning Ratio is -2.1, which is negative.

What is Lantern Pharma Inc Stock Price?

Lantern Pharma Inc Stock Price fell 61.96% and underperformed its sector by 68.59% in the past year.

What is Lantern Pharma Inc Quarterly Net profit?

Lantern Pharma Inc Quarterly Net profit fell 42.52% YoY to $4.51 M. Its sector's average net profit growth YoY for the quarter was -47.41%.

What is Lantern Pharma Inc Debt to Equity Ratio?

Lantern Pharma Inc Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Lantern Pharma Inc Return on Equity(ROE)?

Lantern Pharma Inc Return on Equity(ROE) for the last financial year was -32.93%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Lantern Pharma Inc Mutual Fund Holding?

Lantern Pharma Inc Mutual Fund Holding increased by 0.03% in the last quarter to 8.82.

What is Lantern Pharma Inc Institutional Holding?

Lantern Pharma Inc Institutional Holding increased by 10.79% in the last quarter to 23.18.

How is the Lantern Pharma Inc today?

The Lantern Pharma Inc today is trading in the green, up by 1.92% at 3.72.

How has Lantern Pharma Inc performed historically?

The Lantern Pharma Inc is currently trading up 1.92% on an intraday basis in the past week the index fell 0.00%. The index has been down -0.53% in the past quarter and fell -61.96% in the past year. You can view this in the overview section.

Lantern Pharma Inc XNAS: LTRN

Lantern Pharma Inc Live Share Price Today, Share Analysis and Chart

Name: Lantern Pharma Inc: Is Infosys Ltd. worth buying?
Item: Lantern Pharma Inc
Rating: 1.43058325
Author: Trendlyne DVM scores

Download real time

3.72 0.07 (1.92%)

63.02% Fall from 52W High

20,088 XNAS Volume

XNAS 27 Mar, 2025 5:30 PM (EDT)

Board Meeting

The latest board meeting for Lantern Pharma Inc took place on 27 Mar 2025, for the purpose of Lantern Pharma Inc Annual Report for 2024 See details

Lantern Pharma Inc Key Metrics

My Metrics

Select

Market Capitalization Below industry Median Unavailable in chosen country	40.1
PE TTM Negative PE TTM Unavailable in chosen country	-2.1
PEG TTM Below industry Median Unavailable in chosen country	0.1
Price to Book Below industry Median Unavailable in chosen country	1.5
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	23.2
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-42.5
Net Profit TTM Growth % Negative Net Profit TTM Growth % Unavailable in chosen country	-26
Piotroski Score Below industry Median Unavailable in chosen country	1
Rel Perf vs Sector quarter% Unavailable in chosen country	-4.5
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-32.9
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-31.1

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

8.8 / 100

Technically Neutral

48.4 / 100

No estimates available

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Lantern Pharma Inc Stock Price Analysis

Day Price Range 1.9% 1 Day return Unavailable in chosen country	3.7 (LTP) 3.64 LowHigh
Month Price Range -6.8% 1 Month return Unavailable in chosen country	3.7 (LTP) 3.44 LowHigh
52 Week Price Range -62.0% 1 Year return Unavailable in chosen country	3.7 (LTP) 2.810.1 LowHigh

View full Share Price History

Lantern Pharma Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Lantern Pharma Inc Stock Analysis

Lantern Pharma Inc stock analysis with key metrics, changes, and trends.

Lantern Pharma Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$15.96 M	5.31%	negative	Annual Net Profit fell 5.31% in the last year to $15.96 M. Its sector's average net profit growth for the last fiscal year was -32.45%.
Price to Earning Ratio	-2.1	-	negative	Price to Earning Ratio is -2.1, which is negative.
Stock Price	$3.72	-61.96%	negative	Stock Price fell 61.96% and underperformed its sector by 68.59% in the past year.
Quarterly Net profit	$4.51 M	42.52%	negative	Quarterly Net profit fell 42.52% YoY to $4.51 M. Its sector's average net profit growth YoY for the quarter was -47.41%.
Debt to Equity Ratio	0.01	-	positive	Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-32.93 %	-32.93%	negative	Return on Equity(ROE) for the last financial year was -32.93%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	8.82 %	0.03%	positive	Mutual Fund Holding increased by 0.03% in the last quarter to 8.82.
Institutional Holding	23.18 %	10.79%	positive	Institutional Holding increased by 10.79% in the last quarter to 23.18.

VIEW LESS

Loading data..

Lantern Pharma Inc - Company Profile

What does Lantern Pharma Inc do?

Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.

2022

Gross Remuneration

Year

Lantern Pharma Inc Live Share Price Today, Share Analysis and Chart

63.02% Fall from 52W High

Lantern Pharma Inc Key Metrics

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Lantern Pharma Inc Stock Price Analysis

Day Price Range

Month Price Range

52 Week Price Range

Lantern Pharma Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Lantern Pharma Inc Stock Analysis

Lantern Pharma Inc stock analysis with key metrics, changes, and trends.

Annual Net Profit fell 5.31% in the last year to $15.96 M. Its sector's average net profit growth for the last fiscal year was -32.45%.

Price to Earning Ratio is -2.1, which is negative.

Stock Price fell 61.96% and underperformed its sector by 68.59% in the past year.

Quarterly Net profit fell 42.52% YoY to $4.51 M. Its sector's average net profit growth YoY for the quarter was -47.41%.

Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -32.93%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding increased by 0.03% in the last quarter to 8.82.

Institutional Holding increased by 10.79% in the last quarter to 23.18.

Lantern Pharma Inc - Company Profile

What does Lantern Pharma Inc do?

Lantern Pharma Inc Management structure

Mr. Panna L. Sharma

Chief Executive Officer, President and Director

Mr. David R. Margrave

Principal Accounting Officer, Chief Financial Officer and Secretary

Mr. Kishor G. Bhatia

Chief Scientific Officer

Lantern Pharma Inc Board of directors

Mr. Donald Jeffrey Keyser

Chairman of the Board

Dr. Franklyn G Prendergast

Independent Director

Dr. Vijay Chandru

Independent Director

Mr. David S. Silberstein

Director

Dr. Maria Maccecchini, PhD

Independent Director

Mr. Panna L. Sharma

Chief Executive Officer, President and Director

Lantern Pharma Inc FAQ

How is Lantern Pharma Inc today?

Lantern Pharma Inc today is trading in the green, and is up by 1.92% at 3.72.

How has Lantern Pharma Inc performed historically?

Lantern Pharma Inc is currently trading up 1.92% on an intraday basis. In the past week the stock fell 0.00%. stock has been down -0.53% in the past quarter and fell -61.96% in the past year. You can view this in the overview section.